title: Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma.
abstract: BACKGROUND
  Treatment strategies targeting angiogenesis have revealed promising results in preclinical studies and early clinical trials in patients with glioblastomas.
  
  
  OBJECTIVE
  This review evaluates the preclinical and clinical data for cediranib (AZD2171), a potent oral inhibitor of the VEGF receptor tyrosine kinase.
  
  
  METHODS
  We summarize both preclinical and clinical data for cediranib, with a focus on the treatment of glioblastomas.
  
  
  CONCLUSIONS
  Cediranib is an effective drug in patients with glioblastoma, acting through inhibition of angiogenesis and normalization of tumor vasculature. Reduction of vasogenic brain edema is a key component of its treatment effect in this patient population. The primary side effects of cediranib include fatigue, diarrhea and hypertension.
authors: Stephen E and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.
authors: Jörg
authors: J
authors: Dietrich
authors: Daphne
authors: D
authors: Wang
authors: Tracy T
authors: TT
authors: Batchelor
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D005909:Glioblastoma / Q000098:blood supply / Q000188:drug therapy*; D006801:Humans; D011799:Quinazolines / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D007211:Indoles
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D011799:Quinazolines; D040262:Receptors, Vascular Endothelial Growth Factor; C500926:cediranib; D007211:Indoles